^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    MRDVision

    Company:
    Inocras
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    11d
    Setting a New Standard in MRD Detection: Achieving Parts-per-Million Level Sensitivity with Inocras Whole Genome Platform and Ultima ppmSeqâ"¢ (AMP 2024)
    In addition to comprehensive cancer profiling, Inocras's MRDVision employs the WGS approach for ultra-sensitive, panel-free detection of minimal residual disease (MRD) at the parts-per-million (ppm) level. This workshop explores the clinical integration of Inocras' WGS technology for cancer profiling and MRD detection, demonstrating how our solutions provide actionable insights with broad clinical impact while achieving fast turnaround time and affordability.
    CancerVision • MRDVision